Main > ONCOLOGY (**) > Lymphoma>NHL>T-Cell>sALCL *** > TREAT.: > USA. S. BrentuxiMAb Vedotin>

---

USA. S. BrentuxiMAb Vedotin>'s subsections
(*) EU CE Mark Date: 2020. 05.14
(*) USA Approval Date: 2018. 11.16.
+CT (cyclophosphamide, doxorubicin,
>for Inj.
>Previously Untreated ..
Company
Patents
TradeMark
TradeMark Web-Site

USA. S. BrentuxiMAb Vedotin>'s products
This section has no products